Estrogens are the female sex hormones, but they have also been known to have a well-established link to being carcinogenic and intrinsic in developing hormone-dependent cancers, despite their essential physiological roles in both males and females. Therefore, when prescribing hormones in female patients for contraception or hormonal replacement, the risk of cancer developing in the cervix or the breast must be considered. In contrast, cancers such as colorectal, ovarian, and endometrial cancers have been shown to have a decrease in incidence in women who have used hormonal therapy; however, the mechanism by which this phenomenon is seen is yet to be confirmed. By acquiring a deeper understanding of these physiological pathways, researchers can begin to uncover new therapeutic mechanisms to help prevent cancer progression and treat cancers in otherwise unconsidered ways.
Hormonal therapy in cancer care isn’t a new idea and is already a commonly used therapy in cancers such as prostate and breast cancers. The most common strategies of hormone therapies adopted in cancer care work are either blocking the body’s ability to produce hormones of its own, or interfering with how hormones interact with cancer cells. By identifying new therapies that can block or interfere with estrogen's function within the body, it has the potential to open up new ways to treat cancer or prevent progression without the need for the notoriously unpalatable chemotherapy or radiotherapy. This doesn’t mean that the use of hormone therapy in cancer care is without its risk of adverse effects.
We welcome Original Research, leading-edge Reviews, and Clinical Trials related but not limited to the aspects below:
- New discoveries into how estrogen causes cancer
- New discoveries into how estrogen aids cancer development
- New methods to utilize endocrine therapy in cancer care
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Estrogens are the female sex hormones, but they have also been known to have a well-established link to being carcinogenic and intrinsic in developing hormone-dependent cancers, despite their essential physiological roles in both males and females. Therefore, when prescribing hormones in female patients for contraception or hormonal replacement, the risk of cancer developing in the cervix or the breast must be considered. In contrast, cancers such as colorectal, ovarian, and endometrial cancers have been shown to have a decrease in incidence in women who have used hormonal therapy; however, the mechanism by which this phenomenon is seen is yet to be confirmed. By acquiring a deeper understanding of these physiological pathways, researchers can begin to uncover new therapeutic mechanisms to help prevent cancer progression and treat cancers in otherwise unconsidered ways.
Hormonal therapy in cancer care isn’t a new idea and is already a commonly used therapy in cancers such as prostate and breast cancers. The most common strategies of hormone therapies adopted in cancer care work are either blocking the body’s ability to produce hormones of its own, or interfering with how hormones interact with cancer cells. By identifying new therapies that can block or interfere with estrogen's function within the body, it has the potential to open up new ways to treat cancer or prevent progression without the need for the notoriously unpalatable chemotherapy or radiotherapy. This doesn’t mean that the use of hormone therapy in cancer care is without its risk of adverse effects.
We welcome Original Research, leading-edge Reviews, and Clinical Trials related but not limited to the aspects below:
- New discoveries into how estrogen causes cancer
- New discoveries into how estrogen aids cancer development
- New methods to utilize endocrine therapy in cancer care
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.